BridgeBio Pharma Inc vs Oscar Health Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Oscar Health Inc trades at $27.89 (market cap $8.54B). The key difference: BridgeBio Pharma Inc is the larger of the two by market cap. Which is the better fit depends on your goals.
| BBIO | OSCR | |
|---|---|---|
Market Cap | $16.61B | $8.54B |
Sector | Health | Health |
52-Week High | $90.17 | $32.18 |
52-Week Low | $47.29 | $10.85 |
Enterprise Value | $18.16B | $4.90B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
OSCR trades at $27.90, up 5.12% with strong recent earnings performance including Q2 2026 EPS beating estimates. The stock shows bearish technical signals but positive fundamental momentum with revenue growth from $11.7B to $15.3B and a swing to profitability. Recent news highlights record 2026 profitability and raised full-year guidance.
The outlook appears constructive with analyst consensus target of $32.50 offering 16% upside. Key risks include execution on growth targets and competitive pressures. The valuation remains attractive with P/S of 0.53, though investors should monitor Q3 earnings delivery against expectations.
Trailing returns across standard periods
Latest headlines on both assets
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →Oscar Health, Inc. is a health insurance company that utilizes a technology-driven approach to simplify the healthcare experience. The company offers individual, small-group, and Medicare Advantage plans, primarily through a platform that integrates technology, data, and design to provide members with a personalized, efficient healthcare journey. Oscar aims to lower costs and improve engagement by focusing on consumer-centricity and modernizing the traditional health insurance model.
Read more on OSCR →